Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | EDNRA | P25101 | 10/20 | 0.55 |
| ▸ | F2 | P00734 | 3/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.54 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NSD2 | O96028 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13274117 | 0.88 | CYP1A2 (0.71) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL7022827 | 0.84 | CA2 (0.59) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL1896953 | 0.84 | CA2 (0.64) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL8906929 | 0.83 | CA2 (0.63) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL14539750 | 0.83 | CA2 (0.63) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL3806560 | 0.82 | CYP1A2 (0.63) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL1861706 | 0.81 | CA2 (0.59) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL7558145 | 0.81 | CA2 (0.59) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL5048492 | 0.80 | EDNRA (0.62) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL28956728 | 0.80 | CA2 (0.58) | CA2CYP1A2CYP2C19HTTHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3068405-B1 | PYRROLO [1,2,F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2019-05-01 | — | — | EP | claimed |
| US-9493469-B2 | Piperidine inhibitors of Janus kinase 3 | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | claimed |
| US-11999757-B2 | Synthesis of boronate ester derivatives and uses thereof | MELINTA SUBSIDIARY CORP. (US) | 2024-06-04 | — | — | US | disclosed |
| CN-111556872-B | Synthesis of borate derivatives and uses thereof | 梅琳塔治疗公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-117986153-A | Ionizable cationic lipid compound, and preparation method and application thereof | 晟迪生物医药(苏州)有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-114085243-B | Pyrrolo [1,2-f ] [1,2,4] triazines useful for the treatment of respiratory syncytial virus infection | 吉利德科学公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4356736-A2 | SYNTHESIS OF BORONATE SALTS | Melinta Therapeutics, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-3604316-B1 | SYNTHESIS OF BORONATE SALTS | MELINTA THERAPEUTICS INC (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-2956437-B1 | ALBICIDIN DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | UNIV BERLIN TECH (DE) | 2023-05-10 | — | — | EP | disclosed |
| EP-4122932-A1 | PYRROLO[1,2-F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3505173-B1 | PYRROLO[1,2-F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2022-07-06 | — | — | EP | disclosed |
| WO-2005010075-A2 | METHOD FOR PREPARING FUNCTIONALIZED POLYMERS FROM POLYMER ALCOHOLS | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005000233-A2 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2005-01-06 | — | — | WO | disclosed |
| EP-1485707-A2 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK Pharmaceuticals, Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004064972-A9 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK PHARMACEUTICALS INC (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004064972-A2 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004064745-A2 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | AUSPEX PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2003092581-A9 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK PHARMACEUTICALS INC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2003092581-A2 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| US-20030119021-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999757-B2 | Synthesis of boronate ester derivatives and uses thereof | ADH5, ADH1A, ADH7 | CA2 1540/4885CYP1A2 99/4885CYP2C19 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.